Skip to main content
PMC home page
Microbiological Reviews logoLink to Microbiological Reviews
. 1995 Dec;59(4):591–603. doi: 10.1128/mr.59.4.591-603.1995

Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

E AlonsoDeVelasco 1, A F Verheul 1, J Verhoef 1, H Snippe 1
PMCID: PMC239389  PMID: 8531887

Abstract

Although pneumococcal conjugate vaccines are close to being licensed, a more profound knowledge of the virulence factors responsible for the morbidity and mortality caused by Streptococcus pneumoniae is necessary. This review deals with the major structures of pneumococci involved in the pathogenesis of pneumococcal disease and their interference with the defense mechanisms of the host. It is well known that protection against S. pneumoniae is the result of phagocytosis of invading pathogens. For this process, complement and anticapsular polysaccharide antibodies are required. Besides, relatively recent experimental data suggest that protection is also mediated by the removal of disintegrating pneumococci and their degradation products (cell wall, pneumolysin). These structures seem to be major contributors to illness and death caused by pneumococci. An effective conjugate vaccine should therefore preferably include the capsular polysaccharide and at least one of these inflammatory factors.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. E., Lock R. A., Peeters C. C., Poolman J. T., Andrew P. W., Mitchell T. J., Hansman D., Paton J. C. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun. 1994 Dec;62(12):5683–5688. doi: 10.1128/iai.62.12.5683-5688.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alonso De Velasco E., Dekker B. A., Verheul A. F., Feldman R. G., Verhoef J., Snippe H. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis. 1995 Aug;172(2):562–565. doi: 10.1093/infdis/172.2.562. [DOI] [PubMed] [Google Scholar]
  3. Alonso de Velasco E., Verheul A. F., Veeneman G. H., Gomes L. J., van Boom J. H., Verhoef J., Snippe H. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine. 1993 Nov;11(14):1429–1436. doi: 10.1016/0264-410x(93)90172-t. [DOI] [PubMed] [Google Scholar]
  4. Alonso de Velasco E., Verheul A. F., van Steijn A. M., Dekker H. A., Feldman R. G., Fernández I. M., Kamerling J. P., Vliegenthart J. F., Verhoef J., Snippe H. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG. Infect Immun. 1994 Mar;62(3):799–808. doi: 10.1128/iai.62.3.799-808.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Anderson P. W., Pichichero M. E., Stein E. C., Porcelli S., Betts R. F., Connuck D. M., Korones D., Insel R. A., Zahradnik J. M., Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197. J Immunol. 1989 Apr 1;142(7):2464–2468. [PubMed] [Google Scholar]
  6. Andersson B., Dahmén J., Frejd T., Leffler H., Magnusson G., Noori G., Edén C. S. Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells. J Exp Med. 1983 Aug 1;158(2):559–570. doi: 10.1084/jem.158.2.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Angel C. S., Ruzek M., Hostetter M. K. Degradation of C3 by Streptococcus pneumoniae. J Infect Dis. 1994 Sep;170(3):600–608. doi: 10.1093/infdis/170.3.600. [DOI] [PubMed] [Google Scholar]
  8. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  9. Arnon R., Horwitz R. J. Synthetic peptides as vaccines. Curr Opin Immunol. 1992 Aug;4(4):449–453. doi: 10.1016/s0952-7915(06)80037-3. [DOI] [PubMed] [Google Scholar]
  10. Au C. C., Einsenstein T. K. Evaluation of the role of the pneumococcal Forssman antigen (F-polysaccharide) in the cross-serotype protection induced by pneumococcal subcellular preparations. Infect Immun. 1981 Jan;31(1):169–173. doi: 10.1128/iai.31.1.169-173.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Avery O. T., Dubos R. THE PROTECTIVE ACTION OF A SPECIFIC ENZYME AGAINST TYPE III PNEUMOCOCCUS INFECTION IN MICE. J Exp Med. 1931 Jun 30;54(1):73–89. doi: 10.1084/jem.54.1.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Avery O. T., Goebel W. F. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS. J Exp Med. 1929 Sep 30;50(4):533–550. doi: 10.1084/jem.50.4.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Avery O. T., Macleod C. M., McCarty M. STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III. J Exp Med. 1944 Feb 1;79(2):137–158. doi: 10.1084/jem.79.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Baker P. J., Prescott B., Stashak P. W., Amsbaugh D. F. Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. 3. Studies on the average avidity of the antibody produced by specific plaque-forming cells. J Immunol. 1971 Sep;107(3):719–724. [PubMed] [Google Scholar]
  15. Baker P. J. Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes. Infect Immun. 1990 Nov;58(11):3465–3468. doi: 10.1128/iai.58.11.3465-3468.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Barington T., Gyhrs A., Kristensen K., Heilmann C. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun. 1994 Jan;62(1):9–14. doi: 10.1128/iai.62.1.9-14.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Barington T., Skettrup M., Juul L., Heilmann C. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect Immun. 1993 Feb;61(2):432–438. doi: 10.1128/iai.61.2.432-438.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Barrett D. J., Ayoub E. M. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol. 1986 Jan;63(1):127–134. [PMC free article] [PubMed] [Google Scholar]
  19. Berry A. M., Lock R. A., Hansman D., Paton J. C. Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect Immun. 1989 Aug;57(8):2324–2330. doi: 10.1128/iai.57.8.2324-2330.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Berry A. M., Yother J., Briles D. E., Hansman D., Paton J. C. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun. 1989 Jul;57(7):2037–2042. doi: 10.1128/iai.57.7.2037-2042.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Beuvery E. C., van Rossum F., Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun. 1982 Jul;37(1):15–22. doi: 10.1128/iai.37.1.15-22.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Borgoño J. M., McLean A. A., Vella P. P., Woodhour A. F., Canepa I., Davidson W. L., Hilleman M. R. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med. 1978 Jan;157(1):148–154. doi: 10.3181/00379727-157-40010. [DOI] [PubMed] [Google Scholar]
  23. Boulnois G. J. Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae. J Gen Microbiol. 1992 Feb;138(2):249–259. doi: 10.1099/00221287-138-2-249. [DOI] [PubMed] [Google Scholar]
  24. Briles D. E., Claflin J. L., Schroer K., Forman C. Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature. 1981 Nov 5;294(5836):88–90. doi: 10.1038/294088a0. [DOI] [PubMed] [Google Scholar]
  25. Briles D. E., Forman C., Crain M. Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun. 1992 May;60(5):1957–1962. doi: 10.1128/iai.60.5.1957-1962.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Briles D. E., Forman C., Horowitz J. C., Volanakis J. E., Benjamin W. H., Jr, McDaniel L. S., Eldridge J., Brooks J. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun. 1989 May;57(5):1457–1464. doi: 10.1128/iai.57.5.1457-1464.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Briles D. E., Scott G., Gray B., Crain M. J., Blaese M., Nahm M., Scott V., Haber P. Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides. J Infect Dis. 1987 Jun;155(6):1307–1314. doi: 10.1093/infdis/155.6.1307. [DOI] [PubMed] [Google Scholar]
  28. Briles D. E., Yother J., McDaniel L. S. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 2):S372–S374. doi: 10.1093/cid/10.supplement_2.s372. [DOI] [PubMed] [Google Scholar]
  29. Brown E. J., Hosea S. W., Frank M. M. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis. 1983 Sep-Oct;5 (Suppl 4):S797–S805. doi: 10.1093/clinids/5.supplement_4.s797. [DOI] [PubMed] [Google Scholar]
  30. Bruyn G. A., Zegers B. J., van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis. 1992 Jan;14(1):251–262. doi: 10.1093/clinids/14.1.251. [DOI] [PubMed] [Google Scholar]
  31. Bruyn G. A., van Furth R. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):897–910. doi: 10.1007/BF02005442. [DOI] [PubMed] [Google Scholar]
  32. Carlsen B. D., Kawana M., Kawana C., Tomasz A., Giebink G. S. Role of the bacterial cell wall in middle ear inflammation caused by Streptococcus pneumoniae. Infect Immun. 1992 Jul;60(7):2850–2854. doi: 10.1128/iai.60.7.2850-2854.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Chao D., MacPherson G. G. Analysis of thymus-independent type 2 antigen uptake by marginal zone macrophages in thin slices of viable lymphoid tissue in vitro. Eur J Immunol. 1990 Jul;20(7):1451–1455. doi: 10.1002/eji.1830200707. [DOI] [PubMed] [Google Scholar]
  34. Chudwin D. S., Artrip S. G., Korenblit A., Schiffman G., Rao S. Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae. Infect Immun. 1985 Oct;50(1):213–217. doi: 10.1128/iai.50.1.213-217.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Cottagnoud P., Tomasz A. Triggering of pneumococcal autolysis by lysozyme. J Infect Dis. 1993 Mar;167(3):684–690. doi: 10.1093/infdis/167.3.684. [DOI] [PubMed] [Google Scholar]
  36. Crain M. J., Waltman W. D., 2nd, Turner J. S., Yother J., Talkington D. F., McDaniel L. S., Gray B. M., Briles D. E. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun. 1990 Oct;58(10):3293–3299. doi: 10.1128/iai.58.10.3293-3299.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Cundell D. R., Pearce B. J., Sandros J., Naughton A. M., Masure H. R. Peptide permeases from Streptococcus pneumoniae affect adherence to eucaryotic cells. Infect Immun. 1995 Jul;63(7):2493–2498. doi: 10.1128/iai.63.7.2493-2498.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Cundell D. R., Tuomanen E. I. Receptor specificity of adherence of Streptococcus pneumoniae to human type-II pneumocytes and vascular endothelial cells in vitro. Microb Pathog. 1994 Dec;17(6):361–374. doi: 10.1006/mpat.1994.1082. [DOI] [PubMed] [Google Scholar]
  39. Dagan R., Isaachson M., Lang R., Karpuch J., Block C., Amir J. Epidemiology of pediatric meningitis caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis in Israel: a 3-year nationwide prospective study. Israeli Pediatric Bacteremia and Meningitis Group. J Infect Dis. 1994 Apr;169(4):912–916. doi: 10.1093/infdis/169.4.912. [DOI] [PubMed] [Google Scholar]
  40. Dick W. E., Jr, Beurret M. Glycoconjugates of bacterial carbohydrate antigens. A survey and consideration of design and preparation factors. Contrib Microbiol Immunol. 1989;10:48–114. [PubMed] [Google Scholar]
  41. Douglas R. M., Paton J. C., Duncan S. J., Hansman D. J. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983 Jul;148(1):131–137. doi: 10.1093/infdis/148.1.131. [DOI] [PubMed] [Google Scholar]
  42. Duane P. G., Rubins J. B., Weisel H. R., Janoff E. N. Identification of hydrogen peroxide as a Streptococcus pneumoniae toxin for rat alveolar epithelial cells. Infect Immun. 1993 Oct;61(10):4392–4397. doi: 10.1128/iai.61.10.4392-4397.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Etlinger H. M., Gillessen D., Lahm H. W., Matile H., Schönfeld H. J., Trzeciak A. Use of prior vaccinations for the development of new vaccines. Science. 1990 Jul 27;249(4967):423–425. doi: 10.1126/science.1696030. [DOI] [PubMed] [Google Scholar]
  44. FELTON L. D., KAUFFMANN G., PRESCOTT B., OTTINGER B. Studies on the mechanism of the immunological paralysis induced in mice by pneumococcal polysaccharides. J Immunol. 1955 Jan;74(1):17–26. [PubMed] [Google Scholar]
  45. Feldman C., Mitchell T. J., Andrew P. W., Boulnois G. J., Read R. C., Todd H. C., Cole P. J., Wilson R. The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro. Microb Pathog. 1990 Oct;9(4):275–284. doi: 10.1016/0882-4010(90)90016-j. [DOI] [PubMed] [Google Scholar]
  46. Fernández I. M., Snijders A., Benaissa-Trouw B. J., Harmsen M., Snippe H., Kraaijeveld C. A. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus. J Virol. 1993 Oct;67(10):5843–5848. doi: 10.1128/jvi.67.10.5843-5848.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ferrante A., Rowan-Kelly B., Paton J. C. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun. 1984 Nov;46(2):585–589. doi: 10.1128/iai.46.2.585-589.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Fine D. P. Pneumococcal type-associated variability in alternate complement pathway activation. Infect Immun. 1975 Oct;12(4):772–778. doi: 10.1128/iai.12.4.772-778.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Freijd A., Hammarström L., Persson M. A., Smith C. I. Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children. Clin Exp Immunol. 1984 May;56(2):233–238. [PMC free article] [PubMed] [Google Scholar]
  50. García-Leoni M. E., Cercenado E., Rodeño P., Bernaldo de Quirós J. C., Martínez-Hernández D., Bouza E. Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study. Clin Infect Dis. 1992 Feb;14(2):427–435. doi: 10.1093/clinids/14.2.427. [DOI] [PubMed] [Google Scholar]
  51. Geelen S., Bhattacharyya C., Tuomanen E. The cell wall mediates pneumococcal attachment to and cytopathology in human endothelial cells. Infect Immun. 1993 Apr;61(4):1538–1543. doi: 10.1128/iai.61.4.1538-1543.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Giebink G. S., Verhoef J., Peterson P. K., Quie P. G. Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV. Infect Immun. 1977 Nov;18(2):291–297. doi: 10.1128/iai.18.2.291-297.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Gillespie S. H. Aspects of pneumococcal infection including bacterial virulence, host response and vaccination. J Med Microbiol. 1989 Apr;28(4):237–248. doi: 10.1099/00222615-28-4-237. [DOI] [PubMed] [Google Scholar]
  54. Goebel W. F., Avery O. T. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : I. THE SYNTHESIS OFp-AMINOPHENOL beta-GLUCOSIDE, p-AMINOPHENOL beta-GALACTOSIDE, AND THEIR COUPLING WITH SERUM GLOBULIN. J Exp Med. 1929 Sep 30;50(4):521–531. doi: 10.1084/jem.50.4.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Goebel W. F. STUDIES ON ANTIBACTERIAL IMMUNITY INDUCED BY ARTIFICIAL ANTIGENS : I. IMMUNITY TO EXPERIMENTAL PNEUMOCOCCAL INFECTION WITH AN ANTIGEN CONTAINING CELLOBIURONIC ACID. J Exp Med. 1939 Feb 28;69(3):353–364. doi: 10.1084/jem.69.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Gray B. M., Converse G. M., 3rd, Dillon H. C., Jr Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis. 1980 Dec;142(6):923–933. doi: 10.1093/infdis/142.6.923. [DOI] [PubMed] [Google Scholar]
  57. Gray B. M., Converse G. M., 3rd, Dillon H. C., Jr Serotypes of Streptococcus pneumoniae causing disease. J Infect Dis. 1979 Dec;140(6):979–983. doi: 10.1093/infdis/140.6.979. [DOI] [PubMed] [Google Scholar]
  58. Gray B. M., Converse G. M., 3rd, Huhta N., Johnston R. B., Jr, Pichichero M. E., Schiffman G., Dillon H. C., Jr Epidemiologic studies of Streptococcus pneumoniae in infants: antibody response to nasopharyngeal carriage of types 3, 19, and 23. J Infect Dis. 1981 Oct;144(4):312–318. doi: 10.1093/infdis/144.4.312. [DOI] [PubMed] [Google Scholar]
  59. Gray B. M., Dillon H. C., Jr, Briles D. E. Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. J Clin Microbiol. 1983 Nov;18(5):1102–1107. doi: 10.1128/jcm.18.5.1102-1107.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Gray B. M., Dillon H. C., Jr Epidemiological studies of Streptococcus pneumoniae in infants: antibody to types 3, 6, 14, and 23 in the first two years of life. J Infect Dis. 1988 Nov;158(5):948–955. doi: 10.1093/infdis/158.5.948. [DOI] [PubMed] [Google Scholar]
  61. Griffioen A. W., Rijkers G. T., Janssens-Korpela P., Zegers B. J. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect Immun. 1991 May;59(5):1839–1845. doi: 10.1128/iai.59.5.1839-1845.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Griffioen A. W., Rijkers G. T., Toebes E. A., Zegers B. J. The human in vitro anti-type 4 pneumococcal polysaccharide antibody response is regulated by suppressor T cells. Scand J Immunol. 1991 Aug;34(2):229–236. doi: 10.1111/j.1365-3083.1991.tb01541.x. [DOI] [PubMed] [Google Scholar]
  63. Griffioen A. W., Sanders L., Rijkers G. T., Zegers B. J. Cell biology of B lymphocyte activation by polysaccharides. J Infect Dis. 1992 Jun;165 (Suppl 1):S71–S73. doi: 10.1093/infdis/165-supplement_1-s71. [DOI] [PubMed] [Google Scholar]
  64. Griffioen A. W., Toebes E. A., Zegers B. J., Rijkers G. T. Role of CR2 in the human adult and neonatal in vitro antibody response to type 4 pneumococcal polysaccharide. Cell Immunol. 1992 Aug;143(1):11–22. doi: 10.1016/0008-8749(92)90002-7. [DOI] [PubMed] [Google Scholar]
  65. Harding C. V., Kihlberg J., Elofsson M., Magnusson G., Unanue E. R. Glycopeptides bind MHC molecules and elicit specific T cell responses. J Immunol. 1993 Sep 1;151(5):2419–2425. [PubMed] [Google Scholar]
  66. Harding C. V., Roof R. W., Allen P. M., Unanue E. R. Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2740–2744. doi: 10.1073/pnas.88.7.2740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Hof D. G., Repine J. E., Giebink G. S., Hoidal J. R. Production of opsonins that facilitate phagocytosis of Streptococcus pneumoniae by human alveolar macrophages or neutrophils after vaccination with pneumococcal polysaccharide. Am Rev Respir Dis. 1981 Aug;124(2):193–195. doi: 10.1164/arrd.1981.124.2.193. [DOI] [PubMed] [Google Scholar]
  68. Holzer T. J., Edwards K. M., Gewurz H., Mold C. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis. J Immunol. 1984 Sep;133(3):1424–1430. [PubMed] [Google Scholar]
  69. Horne D., Tomasz A. Pneumococcal Forssman antigen: enrichment in mesosomal membranes and specific binding to the autolytic enzyme of Streptococcus pneumoniae. J Bacteriol. 1985 Jan;161(1):18–24. doi: 10.1128/jb.161.1.18-24.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Hostetter M. K. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis. 1986 Apr;153(4):682–693. doi: 10.1093/infdis/153.4.682. [DOI] [PubMed] [Google Scholar]
  71. Houldsworth S., Andrew P. W., Mitchell T. J. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun. 1994 Apr;62(4):1501–1503. doi: 10.1128/iai.62.4.1501-1503.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Insel R. A., Anderson P. W. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J Exp Med. 1986 Feb 1;163(2):262–269. doi: 10.1084/jem.163.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Ishioka G. Y., Lamont A. G., Thomson D., Bulbow N., Gaeta F. C., Sette A., Grey H. M. MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol. 1992 Apr 15;148(8):2446–2451. [PubMed] [Google Scholar]
  74. Jalonen E., Paton J. C., Koskela M., Kerttula Y., Leinonen M. Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect. 1989 Sep;19(2):127–134. doi: 10.1016/s0163-4453(89)91864-1. [DOI] [PubMed] [Google Scholar]
  75. Jennings H. J., Lugowski C., Young N. M. Structure of the complex polysaccharide C-substance from Streptococcus pneumoniae type 1. Biochemistry. 1980 Sep 30;19(20):4712–4719. doi: 10.1021/bi00561a026. [DOI] [PubMed] [Google Scholar]
  76. Johnston R. B., Jr Pathogenesis of pneumococcal pneumonia. Rev Infect Dis. 1991 May-Jun;13 (Suppl 6):S509–S517. doi: 10.1093/clinids/13.supplement_6.s509. [DOI] [PubMed] [Google Scholar]
  77. Johnston R. B., Newman S. L. Chronic granulomatous disease. Pediatr Clin North Am. 1977 May;24(2):365–376. doi: 10.1016/s0031-3955(16)33424-1. [DOI] [PubMed] [Google Scholar]
  78. Kabat E. A., Liao J., Osserman E. F., Gamian A., Michon F., Jennings H. J. The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgMNOV. J Exp Med. 1988 Aug 1;168(2):699–711. doi: 10.1084/jem.168.2.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Kelly T., Dillard J. P., Yother J. Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect Immun. 1994 May;62(5):1813–1819. doi: 10.1128/iai.62.5.1813-1819.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Kenny J. J., Guelde G., Fischer R. T., Longo D. L. Induction of phosphocholine-specific antibodies in X-linked immune deficient mice: in vivo protection against a Streptococcus pneumoniae challenge. Int Immunol. 1994 Apr;6(4):561–568. doi: 10.1093/intimm/6.4.561. [DOI] [PubMed] [Google Scholar]
  81. Kornfeld S. J., Plaut A. G. Secretory immunity and the bacterial IgA proteases. Rev Infect Dis. 1981 May-Jun;3(3):521–534. doi: 10.1093/clinids/3.3.521. [DOI] [PubMed] [Google Scholar]
  82. Krivan H. C., Roberts D. D., Ginsburg V. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6157–6161. doi: 10.1073/pnas.85.16.6157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985 Apr 11;314(6011):537–539. doi: 10.1038/314537a0. [DOI] [PubMed] [Google Scholar]
  84. Lee C. J. Bacterial capsular polysaccharides--biochemistry, immunity and vaccine. Mol Immunol. 1987 Oct;24(10):1005–1019. doi: 10.1016/0161-5890(87)90067-8. [DOI] [PubMed] [Google Scholar]
  85. Lett E., Gangloff S., Zimmermann M., Wachsmann D., Klein J. P. Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes. Infect Immun. 1994 Mar;62(3):785–792. doi: 10.1128/iai.62.3.785-792.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Lindsten T., Andersson B. Studies on functional subpopulations of B cells in mice. Correction of the immune defect of CBA/N mice by transfer of C3 receptor-bearing B cells. Cell Immunol. 1981 Jul 1;61(2):386–396. doi: 10.1016/0008-8749(81)90386-5. [DOI] [PubMed] [Google Scholar]
  87. Lock R. A., Hansman D., Paton J. C. Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb Pathog. 1992 Feb;12(2):137–143. doi: 10.1016/0882-4010(92)90116-6. [DOI] [PubMed] [Google Scholar]
  88. Lock R. A., Paton J. C., Hansman D. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae. Microb Pathog. 1988 Dec;5(6):461–467. doi: 10.1016/0882-4010(88)90007-1. [DOI] [PubMed] [Google Scholar]
  89. Marguerite M., Bossus M., Mazingue C., Wolowczuk I., Gras-Masse H., Tartar A., Capron A., Auriault C. Analysis of antigenicity and immunogenicity of five different chemically defined constructs of a peptide. Mol Immunol. 1992 Jun;29(6):793–800. doi: 10.1016/0161-5890(92)90189-5. [DOI] [PubMed] [Google Scholar]
  90. Matthay K. K., Mentzer W. C., Wara D. W., Preisler H. K., Lameris N. B., Ammann A. J. Evaluation of the opsonic requirements for phagocytosis of Streptococcus pneumoniae serotypes VII, XIV, and XIX by chemiluminescence assay. Infect Immun. 1981 Jan;31(1):228–235. doi: 10.1128/iai.31.1.228-235.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. McDaniel L. S., Scott G., Kearney J. F., Briles D. E. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med. 1984 Aug 1;160(2):386–397. doi: 10.1084/jem.160.2.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. McDaniel L. S., Sheffield J. S., Delucchi P., Briles D. E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun. 1991 Jan;59(1):222–228. doi: 10.1128/iai.59.1.222-228.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. McDaniel L. S., Yother J., Vijayakumar M., McGarry L., Guild W. R., Briles D. E. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med. 1987 Feb 1;165(2):381–394. doi: 10.1084/jem.165.2.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Mold C., Nakayama S., Holzer T. J., Gewurz H., Du Clos T. W. C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med. 1981 Nov 1;154(5):1703–1708. doi: 10.1084/jem.154.5.1703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Mouritsen S., Meldal M., Christiansen-Brams I., Elsner H., Werdelin O. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex class II molecules and peptide immunogenicity. Eur J Immunol. 1994 May;24(5):1066–1072. doi: 10.1002/eji.1830240509. [DOI] [PubMed] [Google Scholar]
  96. Musher D. M., Groover J. E., Rowland J. M., Watson D. A., Struewing J. B., Baughn R. E., Mufson M. A. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis. 1993 Jul;17(1):66–73. doi: 10.1093/clinids/17.1.66. [DOI] [PubMed] [Google Scholar]
  97. Musher D. M. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis. 1992 Apr;14(4):801–807. doi: 10.1093/clinids/14.4.801. [DOI] [PubMed] [Google Scholar]
  98. Musher D. M., Johnson B., Jr, Watson D. A. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun. 1990 Dec;58(12):3871–3876. doi: 10.1128/iai.58.12.3871-3876.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Musher D. M., Luchi M. J., Watson D. A., Hamilton R., Baughn R. E. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis. 1990 Apr;161(4):728–735. doi: 10.1093/infdis/161.4.728. [DOI] [PubMed] [Google Scholar]
  100. Musher D. M., Watson D. A., Baughn R. E. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis. 1990 Apr;161(4):736–740. doi: 10.1093/infdis/161.4.736. [DOI] [PubMed] [Google Scholar]
  101. Nicoletti C., Yang X., Cerny J. Repertoire diversity of antibody response to bacterial antigens in aged mice. III. Phosphorylcholine antibody from young and aged mice differ in structure and protective activity against infection with Streptococcus pneumoniae. J Immunol. 1993 Jan 15;150(2):543–549. [PubMed] [Google Scholar]
  102. Nielsen S. V., Sørensen U. B., Henrichsen J. Antibodies against pneumococcal C-polysaccharide are not protective. Microb Pathog. 1993 Apr;14(4):299–305. doi: 10.1006/mpat.1993.1029. [DOI] [PubMed] [Google Scholar]
  103. Noelle R. J., Snow E. C. T helper cell-dependent B cell activation. FASEB J. 1991 Oct;5(13):2770–2776. doi: 10.1096/fasebj.5.13.1833257. [DOI] [PubMed] [Google Scholar]
  104. Ofek I., Sharon N. Lectinophagocytosis: a molecular mechanism of recognition between cell surface sugars and lectins in the phagocytosis of bacteria. Infect Immun. 1988 Mar;56(3):539–547. doi: 10.1128/iai.56.3.539-547.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Paoletti L. C., Kasper D. L., Michon F., DiFabio J., Jennings H. J., Tosteson T. D., Wessels M. R. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 1992 Jan;89(1):203–209. doi: 10.1172/JCI115564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Paton J. C., Andrew P. W., Boulnois G. J., Mitchell T. J. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Annu Rev Microbiol. 1993;47:89–115. doi: 10.1146/annurev.mi.47.100193.000513. [DOI] [PubMed] [Google Scholar]
  107. Paton J. C., Ferrante A. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immun. 1983 Sep;41(3):1212–1216. doi: 10.1128/iai.41.3.1212-1216.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Paton J. C., Lock R. A., Hansman D. J. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun. 1983 May;40(2):548–552. doi: 10.1128/iai.40.2.548-552.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Paton J. C., Lock R. A., Lee C. J., Li J. P., Berry A. M., Mitchell T. J., Andrew P. W., Hansman D., Boulnois G. J. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun. 1991 Jul;59(7):2297–2304. doi: 10.1128/iai.59.7.2297-2304.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Paul W. E., Katz D. H., Benacerraf B. Augmented anti-S 3 antibody responses to an S 3 -protein conjugate. J Immunol. 1971 Sep;107(3):685–688. [PubMed] [Google Scholar]
  111. Peeters C. C., Tenbergen-Meekes A. M., Evenberg D. E., Poolman J. T., Zegers B. J., Rijkers G. T. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J Immunol. 1991 Jun 15;146(12):4308–4314. [PubMed] [Google Scholar]
  112. Peeters C. C., Tenbergen-Meekes A. M., Poolman J. T., Beurret M., Zegers B. J., Rijkers G. T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun. 1991 Oct;59(10):3504–3510. doi: 10.1128/iai.59.10.3504-3510.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Perlmutter R. M., Hansburg D., Briles D. E., Nicolotti R. A., Davie J. M. Subclass restriction of murine anti-carbohydrate antibodies. J Immunol. 1978 Aug;121(2):566–572. [PubMed] [Google Scholar]
  114. Plotkowski M. C., Puchelle E., Beck G., Jacquot J., Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis. 1986 Nov;134(5):1040–1044. doi: 10.1164/arrd.1986.134.5.1040. [DOI] [PubMed] [Google Scholar]
  115. Renneberg J., Svinhufvud M., Prellner K., Christensen P. Western blot analysis of immunoglobulin G antibodies to pneumococcal protein antigens in healthy adults. Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):73–76. doi: 10.1007/BF01964411. [DOI] [PubMed] [Google Scholar]
  116. Richter A. W., Eby R. Studies on artificial oligosaccharide-protein antigens: induction of precipitating antibodies to defined epitopes on natural and synthetic dextrans and mannans. Mol Immunol. 1985 Jan;22(1):29–36. doi: 10.1016/0161-5890(85)90031-8. [DOI] [PubMed] [Google Scholar]
  117. Riesenfeld-Orn I., Wolpe S., Garcia-Bustos J. F., Hoffmann M. K., Tuomanen E. Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun. 1989 Jul;57(7):1890–1893. doi: 10.1128/iai.57.7.1890-1893.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Rijkers G. T., Roord J. J., Struyvé M. C., Poolman J. T., Zegers B. J. Development of IgG antipolyribosylribitolphosphate antibodies in the course of H. influenzae type b meningitis in infants below 2 years of age. Monogr Allergy. 1988;23:282–288. [PubMed] [Google Scholar]
  119. Rivier D. A., Trefts P. E., Cook K. A. In vivo isotype regulation of humoral responses to dextran B1355 in BALB/c mice. Double-class IgG3/IgM producers as a function of age. Scand J Immunol. 1985 Feb;21(2):173–181. doi: 10.1111/j.1365-3083.1985.tb01417.x. [DOI] [PubMed] [Google Scholar]
  120. Rubins J. B., Duane P. G., Clawson D., Charboneau D., Young J., Niewoehner D. E. Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun. 1993 Apr;61(4):1352–1358. doi: 10.1128/iai.61.4.1352-1358.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Sanders L. A., Rijkers G. T., Kuis W., Tenbergen-Meekes A. J., de Graeff-Meeder B. R., Hiemstra I., Zegers B. J. Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol. 1993 Jan;91(1 Pt 1):110–119. doi: 10.1016/0091-6749(93)90303-w. [DOI] [PubMed] [Google Scholar]
  122. Schiffman G. Pneumococcal vaccine: a tool for the evaluation of the B-cell function of the immune system. Proc Soc Exp Biol Med. 1983 Dec;174(3):309–315. doi: 10.3181/00379727-174-41742. [DOI] [PubMed] [Google Scholar]
  123. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Sela M., Mozes E., Shearer G. M. Thymus-independence of slowly metabolized immunogens. Proc Natl Acad Sci U S A. 1972 Sep;69(9):2696–2700. doi: 10.1073/pnas.69.9.2696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Seppälä I. J., Routonen N., Sarnesto A., Mattila P. A., Mäkelä O. The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay. Eur J Immunol. 1984 Sep;14(9):868–875. doi: 10.1002/eji.1830140918. [DOI] [PubMed] [Google Scholar]
  126. Seppälä I., Mäkelä O. Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J Immunol. 1989 Aug 15;143(4):1259–1264. [PubMed] [Google Scholar]
  127. Seppälä I., Pelkonen J., Mäkelä O. Isotypes of antibodies induced by plain dextran or a dextran-protein conjugate. Eur J Immunol. 1985 Aug;15(8):827–833. doi: 10.1002/eji.1830150816. [DOI] [PubMed] [Google Scholar]
  128. Seppälä I., Sarvas H., Mäkelä O., Mattila P., Eskola J., Käyhty H. Human antibody responses to two conjugate vaccines of Haemophilus influenzae type B saccharides and diphtheria toxin. Scand J Immunol. 1988 Oct;28(4):471–479. doi: 10.1111/j.1365-3083.1988.tb01478.x. [DOI] [PubMed] [Google Scholar]
  129. Silvennoinen-Kassinen S., Koskela M. Optimal conditions for the opsonophagocytosis test with Streptococcus pneumoniae serotypes 3, 6A, 7F and 19F and human granulocytes. Acta Pathol Microbiol Immunol Scand C. 1986 Jun;94(3):105–111. doi: 10.1111/j.1699-0463.1986.tb02098.x. [DOI] [PubMed] [Google Scholar]
  130. Skov Sørensen U. B., Blom J., Birch-Andersen A., Henrichsen J. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect Immun. 1988 Aug;56(8):1890–1896. doi: 10.1128/iai.56.8.1890-1896.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Smit P., Oberholzer D., Hayden-Smith S., Koornhof H. J., Hilleman M. R. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977 Dec 12;238(24):2613–2616. [PubMed] [Google Scholar]
  132. Snapper C. M., Mond J. J. Towards a comprehensive view of immunoglobulin class switching. Immunol Today. 1993 Jan;14(1):15–17. doi: 10.1016/0167-5699(93)90318-F. [DOI] [PubMed] [Google Scholar]
  133. Snippe H., van Houte A. J., van Dam J. E., De Reuver M. J., Jansze M., Willers J. M. Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Infect Immun. 1983 Jun;40(3):856–861. doi: 10.1128/iai.40.3.856-861.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Stein K. E. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992 Jun;165 (Suppl 1):S49–S52. doi: 10.1093/infdis/165-supplement_1-s49. [DOI] [PubMed] [Google Scholar]
  135. Steinhoff M. C., Edwards K., Keyserling H., Thoms M. L., Johnson C., Madore D., Hogerman D. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J. 1994 May;13(5):368–372. doi: 10.1097/00006454-199405000-00007. [DOI] [PubMed] [Google Scholar]
  136. Stäb F., Austrup F., Kölsch E. Regulation of the anti-alpha(1----3) dextran IgG antibody response of BALB/c mice by idiotype-specific T suppressor lymphocytes. J Immunol. 1990 Jan 1;144(1):53–59. [PubMed] [Google Scholar]
  137. Szu S. C., Schneerson R., Robbins J. B. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun. 1986 Nov;54(2):448–455. doi: 10.1128/iai.54.2.448-455.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Sørensen U. B., Agger R., Bennedsen J., Henrichsen J. Phosphorylcholine determinants in six pneumococcal capsular polysaccharides detected by monoclonal antibody. Infect Immun. 1984 Mar;43(3):876–878. doi: 10.1128/iai.43.3.876-878.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Sørensen U. B., Henrichsen J., Chen H. C., Szu S. C. Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods. Microb Pathog. 1990 May;8(5):325–334. doi: 10.1016/0882-4010(90)90091-4. [DOI] [PubMed] [Google Scholar]
  140. Talkington D. F., Crimmins D. L., Voellinger D. C., Yother J., Briles D. E. A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun. 1991 Apr;59(4):1285–1289. doi: 10.1128/iai.59.4.1285-1289.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Talkington D. F., Voellinger D. C., McDaniel L. S., Briles D. E. Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog. 1992 Nov;13(5):343–355. doi: 10.1016/0882-4010(92)90078-3. [DOI] [PubMed] [Google Scholar]
  142. Tarkowski A., Lue C., Moldoveanu Z., Kiyono H., McGhee J. R., Mestecky J. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. J Immunol. 1990 May 15;144(10):3770–3778. [PubMed] [Google Scholar]
  143. Timens W., Boes A., Rozeboom-Uiterwijk T., Poppema S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol. 1989 Nov 15;143(10):3200–3206. [PubMed] [Google Scholar]
  144. Tomasz A. Surface components of Streptococcus pneumoniae. Rev Infect Dis. 1981 Mar-Apr;3(2):190–211. doi: 10.1093/clinids/3.2.190. [DOI] [PubMed] [Google Scholar]
  145. Tuomanen E., Liu H., Hengstler B., Zak O., Tomasz A. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis. 1985 May;151(5):859–868. doi: 10.1093/infdis/151.5.859. [DOI] [PubMed] [Google Scholar]
  146. Tuomanen E., Rich R., Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis. 1987 Apr;135(4):869–874. doi: 10.1164/arrd.1987.135.4.869. [DOI] [PubMed] [Google Scholar]
  147. Verheul A. F., Versteeg A. A., De Reuver M. J., Jansze M., Snippe H. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect Immun. 1989 Apr;57(4):1078–1083. doi: 10.1128/iai.57.4.1078-1083.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Vitharsson G., Jónsdóttir I., Jónsson S., Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis. 1994 Sep;170(3):592–599. doi: 10.1093/infdis/170.3.592. [DOI] [PubMed] [Google Scholar]
  149. Watson D. A., Musher D. M. Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916. Infect Immun. 1990 Sep;58(9):3135–3138. doi: 10.1128/iai.58.9.3135-3138.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Watson D. A., Musher D. M., Jacobson J. W., Verhoef J. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis. 1993 Nov;17(5):913–924. doi: 10.1093/clinids/17.5.913. [DOI] [PubMed] [Google Scholar]
  151. Wessels M. R., Kasper D. L. Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide. J Exp Med. 1989 Jun 1;169(6):2121–2131. doi: 10.1084/jem.169.6.2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Winkelstein J. A., Tomasz A. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol. 1978 Jan;120(1):174–178. [PubMed] [Google Scholar]
  153. Winkelstein J. A., Tomasz A. Activation of the alternative pathway by pneumococcal cell walls. J Immunol. 1977 Feb;118(2):451–454. [PubMed] [Google Scholar]
  154. Yother J., Volanakis J. E., Briles D. E. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol. 1982 May;128(5):2374–2376. [PubMed] [Google Scholar]
  155. Zigterman G. J., Schotanus K., Ernste E. B., Van Dam G. J., Jansze M., Snippe H., Willers J. M. Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates. Infect Immun. 1989 Sep;57(9):2712–2718. doi: 10.1128/iai.57.9.2712-2718.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. de Velasco E. A., Merkus D., Anderton S., Verheul A. F., Lizzio E. F., Van der Zee R., Van Eden W., Hoffman T., Verhoef J., Snippe H. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines. Infect Immun. 1995 Mar;63(3):961–968. doi: 10.1128/iai.63.3.961-968.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. van Dam J. E., Fleer A., Snippe H. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek. 1990 Jun;58(1):1–47. doi: 10.1007/BF02388078. [DOI] [PubMed] [Google Scholar]
  158. van de Wijgert J. H., Verheul A. F., Snippe H., Check I. J., Hunter R. L. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution. Infect Immun. 1991 Aug;59(8):2750–2757. doi: 10.1128/iai.59.8.2750-2757.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Microbiological Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES